Beginning in the mid-1990s and continuing to the present day, there has been renewed interest and research into psychedelic drugs. One theory that has been given new life is the possibility that the hallucinogen dimethyltryptamine (DMT) is an ‘endogenous psychotogen’, or a substance produced by the body that causes schizophrenia. As you may know, DMT is present in humans and this theory was initially proposed shortly after DMT-forming enzymes were found to be present in mammalian tissues in 1961. Research into DMT continued in the subsequent decades but ended when it was found that DMT concentrations were generally no higher in schizophrenics than in healthy controls. Here we’ll briefly examine this theory in light of new evidence, and demonstrate that a possible role of DMT in schizophrenia still remains viable. This article will be expanded upon in my presentation. Refer to Wong and Van Tol for a good overview of schizophrenia.